Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

3 terminated/withdrawn out of 15 trials

Success Rate

76.9%

-9.6% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

10%

1 of 10 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

11(73.3%)

Phase 1

2(13.3%)

Phase 3

2(13.3%)

15Total

Phase 2(11)

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT02470468Phase 1Completed

Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer

Role: lead

NCT02107937Phase 2Completed

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

Role: lead

NCT03905902Phase 3Withdrawn

DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Role: lead

NCT04834544Phase 2Recruiting

A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

Role: collaborator

NCT03657966Phase 2Completed

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Role: lead

NCT02111577Phase 3Completed

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT03514836Phase 1Terminated

A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT02107430Phase 2Completed

Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer

Role: lead

NCT02107950Phase 2Completed

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Role: lead

NCT02107391Phase 2Completed

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

Role: lead

NCT02105675Phase 2Completed

Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT02137746Phase 2Completed

Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer

Role: lead

NCT02107404Phase 2Completed

Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer

Role: lead

NCT02107378Phase 2Terminated

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Role: lead

NCT02669719Phase 2Unknown

Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC

Role: collaborator

All 15 trials loaded